Steffi B.
- Country
- Germany
- Department
- Frauenheilkunde und Geburtshilfe
Research Overview
- Phase III Randomized, Double-Blind Trial of Atezolizumab with Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients
- EORTC 2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
- A Phase 3 Randomized Study of Sacituzumab Govitecan and Pembrolizumab Versus Physician's Choice in Triple Negative Breast Cancer with Residual Invasive Disease
Data & Insights
Has run more than one trial at 113 of 355 partner sites.
Specializations
Breast Cancer Treatment Innovation
This investigator specializes in advancing therapeutic approaches for early-stage breast cancer, with particular emphasis on endocrine therapy and novel treatment combinations.
- ER+/HER2- Breast Cancer Management
- Triple-Negative Breast Cancer Treatment
- BRCA-Mutated Breast Cancer Therapy
The research focuses on evaluating emerging therapeutic agents for various breast cancer subtypes.
Targeted Therapeutic Approaches
The investigator explores personalized treatment strategies including immunotherapy and targeted molecular therapies for breast cancer patients.
- Neoadjuvant Chemotherapy Combinations
- Adjuvant Treatment Optimization
- Molecular-Based Treatment Selection
Research activities encompass both early-stage interventions and advanced therapeutic protocols.
Biomarker-Driven Research
Specialization in biomarker-guided treatment approaches, including ctDNA analysis and genetic mutation assessment in breast cancer.
- Circulating Tumor DNA Monitoring
- Germline BRCA Mutation Analysis
- Treatment Response Assessment
The investigator integrates molecular diagnostics with therapeutic decision-making.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.